149 related articles for article (PubMed ID: 35962138)
1. Effects of a novel toll-like receptor 4 antagonist IAXO-102 in a murine model of chemotherapy-induced gastrointestinal toxicity.
Tam JSY; Crame EE; Elz AS; Coller JK; Wignall A; Prestidge CA; Bowen JM
Cancer Chemother Pharmacol; 2022 Sep; 90(3):267-278. PubMed ID: 35962138
[TBL] [Abstract][Full Text] [Related]
2. A novel small molecule TLR4 antagonist (IAXO-102) negatively regulates non-hematopoietic toll like receptor 4 signalling and inhibits aortic aneurysms development.
Huggins C; Pearce S; Peri F; Neumann F; Cockerill G; Pirianov G
Atherosclerosis; 2015 Oct; 242(2):563-70. PubMed ID: 26318106
[TBL] [Abstract][Full Text] [Related]
3. Amitriptyline prevents CPT-11-induced early-onset diarrhea and colonic apoptosis without reducing overall gastrointestinal damage in a rat model of mucositis.
Fakiha K; Coller JK; Logan RM; Gibson RJ; Bowen JM
Support Care Cancer; 2019 Jun; 27(6):2313-2320. PubMed ID: 30350190
[TBL] [Abstract][Full Text] [Related]
4. Investigation of TLR4 Antagonists for Prevention of Intestinal Inflammation.
Tam JSY; Coller JK; Prestidge CA; Bowen JM
Inflammation; 2023 Feb; 46(1):103-114. PubMed ID: 35867263
[TBL] [Abstract][Full Text] [Related]
5. Selective Toll-Like Receptor 4 Antagonists Prevent Acute Blood-Brain Barrier Disruption After Subarachnoid Hemorrhage in Mice.
Okada T; Kawakita F; Nishikawa H; Nakano F; Liu L; Suzuki H
Mol Neurobiol; 2019 Feb; 56(2):976-985. PubMed ID: 29855971
[TBL] [Abstract][Full Text] [Related]
6. Structural insight and analysis of TLR4 interactions with IAXO-102, TAK-242 and SN-38: an in silico approach.
Tam JSY; Pei JV; Coller JK; Prestidge CA; Bowen JM
In Silico Pharmacol; 2023; 11(1):1. PubMed ID: 36438853
[TBL] [Abstract][Full Text] [Related]
7. Intestinal toll-like receptor 4 knockout alters the functional capacity of the gut microbiome following irinotecan treatment.
Secombe KR; Crame EE; Tam JSY; Wardill HR; Gibson RJ; Coller JK; Bowen JM
Cancer Chemother Pharmacol; 2022 Feb; 89(2):275-281. PubMed ID: 34854953
[TBL] [Abstract][Full Text] [Related]
8. TLR4 deficiency upregulates TLR9 expression and enhances irinotecan-related intestinal mucositis and late-onset diarrhoea.
Wong DVT; Holanda RBF; Cajado AG; Bandeira AM; Pereira JFB; Amorim JO; Torres CS; Ferreira LMM; Lopes MHS; Oliveira RTG; Pereira AF; Sant'Ana RO; Arruda LM; Ribeiro-Júnior HL; Pinheiro RF; Almeida PRC; Carvalho RF; Chaves FF; Rocha-Filho DR; Cunha FQ; Lima-Júnior RCP
Br J Pharmacol; 2021 Oct; 178(20):4193-4209. PubMed ID: 34216140
[TBL] [Abstract][Full Text] [Related]
9. Paraprobiotic Enterococcus faecalis EC-12 prevents the development of irinotecan-induced intestinal mucositis in mice.
Nobre LMS; da Silva Lopes MH; Geraix J; Cajado AG; Silva JMR; Ribeiro LR; Freire RS; Cavalcante DIM; Wong DVT; Alves APNN; Lima-Júnior RCP
Life Sci; 2022 May; 296():120445. PubMed ID: 35245522
[TBL] [Abstract][Full Text] [Related]
10. Preventative effects of selenium-enriched
Qiu Y; Zhang J; Ji R; Zhou Y; Shao L; Chen D; Tan J
Benef Microbes; 2019 May; 10(5):569-577. PubMed ID: 30964326
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms.
Wardill HR; Gibson RJ; Van Sebille YZ; Secombe KR; Coller JK; White IA; Manavis J; Hutchinson MR; Staikopoulos V; Logan RM; Bowen JM
Mol Cancer Ther; 2016 Jun; 15(6):1376-86. PubMed ID: 27197307
[TBL] [Abstract][Full Text] [Related]
12. Glycolipid-based TLR4 Modulators and Fluorescent Probes: Rational Design, Synthesis, and Biological Properties.
Ciaramelli C; Calabrese V; Sestito SE; Pérez-Regidor L; Klett J; Oblak A; Jerala R; Piazza M; Martín-Santamaría S; Peri F
Chem Biol Drug Des; 2016 Aug; 88(2):217-29. PubMed ID: 26896420
[TBL] [Abstract][Full Text] [Related]
13. Role of toll-like receptor 4 (TLR4)-mediated interleukin-6 (IL-6) production in chemotherapy-induced mucositis.
Khan S; Wardill HR; Bowen JM
Cancer Chemother Pharmacol; 2018 Jul; 82(1):31-37. PubMed ID: 29845394
[TBL] [Abstract][Full Text] [Related]
14. Darunavir alleviates irinotecan-induced intestinal toxicity in Vivo.
Zhang X; Zhang G; Ren Y; Lan T; Li D; Tian J; Jiang W
Eur J Pharmacol; 2018 Sep; 834():288-294. PubMed ID: 30053408
[TBL] [Abstract][Full Text] [Related]
15. Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide.
Melo ML; Brito GA; Soares RC; Carvalho SB; Silva JV; Soares PM; Vale ML; Souza MH; Cunha FQ; Ribeiro RA
Cancer Chemother Pharmacol; 2008 Apr; 61(5):775-84. PubMed ID: 17624531
[TBL] [Abstract][Full Text] [Related]
16. Effects of Toll-Like Receptor 4 Antagonists Against Cerebral Vasospasm After Experimental Subarachnoid Hemorrhage in Mice.
Kawakita F; Fujimoto M; Liu L; Nakano F; Nakatsuka Y; Suzuki H
Mol Neurobiol; 2017 Oct; 54(8):6624-6633. PubMed ID: 27738873
[TBL] [Abstract][Full Text] [Related]
17. Toll-Like Receptor-4 Inhibitor TAK-242 Attenuates Motor Dysfunction and Spinal Cord Pathology in an Amyotrophic Lateral Sclerosis Mouse Model.
Fellner A; Barhum Y; Angel A; Perets N; Steiner I; Offen D; Lev N
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28763002
[TBL] [Abstract][Full Text] [Related]
18. Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report.
Coller JK; Bowen JM; Ball IA; Wardill HR; van Sebille YZ; Stansborough RL; Lightwala Z; Wignall A; Shirren J; Secombe K; Gibson RJ
Cancer Chemother Pharmacol; 2017 Feb; 79(2):431-434. PubMed ID: 28011980
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptors in the pathogenesis of chemotherapy-induced gastrointestinal toxicity.
Cario E
Curr Opin Support Palliat Care; 2016 Jun; 10(2):157-64. PubMed ID: 26986508
[TBL] [Abstract][Full Text] [Related]
20. Carvacrol reduces irinotecan-induced intestinal mucositis through inhibition of inflammation and oxidative damage via TRPA1 receptor activation.
Alvarenga EM; Souza LK; Araújo TS; Nogueira KM; Sousa FB; Araújo AR; Martins CS; Pacífico DM; de C Brito GA; Souza EP; Sousa DP; Medeiros JV
Chem Biol Interact; 2016 Dec; 260():129-140. PubMed ID: 27838229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
